Hikma Pharmaceuticals Public annual shareholders’ equity
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Shareholders’ Equity Growth & History (HIK)
Hikma Pharmaceuticals Public's shareholders’ equity was $2.59B for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.59B | $283.0M | +12.25% |
| 2024 | 2024-12-31 | $2.31B | $112.0M | +5.10% |
| 2023 | 2023-12-31 | $2.20B | $63.0M | +2.95% |
| 2022 | 2022-12-31 | $2.13B | −$318.0M | −12.96% |
| 2021 | 2021-12-31 | $2.45B | $318.0M | +14.89% |
| 2020 | 2020-12-31 | $2.13B | — | — |
Hikma Pharmaceuticals Public quarterly shareholders’ equity
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.52B | −$15.0M | −0.59% |
| Q4 2025 | 2025-12-31 | $2.59B | $283.0M | +12.25% |
| Q2 2025 | 2025-06-30 | $2.54B | — | — |
| Q4 2024 | 2024-12-31 | $2.31B | — | — |
Hikma Pharmaceuticals Public shareholders’ equity trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's shareholders’ equity increased from $2.13B to $2.59B, a change of $458.0M. The latest reported quarter, Q2 2026, shows $2.52B.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company official filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...